Are Inhaled Corticosteroids and Inhaled Corticosteroids/Long-acting β-Agonist of Use in Acute Asthma: an Update on Evidence
- 2 Downloads
Purpose of review
Treatment of acute asthma exacerbations involves using systemic corticosteroids and short-acting β2-agonists (SABA). In an effort to limit the burden of systemic steroids, recent studies suggest benefit with the use of inhaled corticosteroids in an acute asthma exacerbation.
Recent data has demonstrated benefit from the addition of inhaled corticosteroids to systemic steroids, increasing inhaled corticosteroid dose, and adding a separate inhaled corticosteroid inhaler during an exacerbation. Additionally, inhaled corticosteroid and fast-acting long-acting β-agonist (LABA) can be helpful when used in place of a SABA as a reliever of acute symptoms.
This review summarizes recent data that demonstrates potential uses of inhaled corticosteroids and inhaled corticosteroids/LABA for the treatment of acute asthma. Further studies are necessary to evaluate the role of inhaled corticosteroids alone and in combination with SABA and LABA across all asthma severities.
KeywordsAsthma exacerbation Inhaled corticosteroids Inhaled corticosteroids/long-acting beta agonist
Compliance with ethical standards
Conflict of interest
Bradley Chipps serves as a consultant and a member of speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, Regeneron, Sanofi, and TEVA. Neil Parikh serves as a member of speaker’s bureau for Optinose and as a consultant for Astrazeneca, Aimmune, CSL Behring, Theravance. Sheena Maharaj and Travis Russell declare that they have no conflict of interest.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.Global Initiative for Asthma. Global strategy for asthma management and prevention; 2019. Available from: www.ginasthma.org. Accessed 9 July 2019.
- 5.U.S. Department of Health and Human Services, National Institutes of Health [Internet]. Expert Panel Report 3: guidelines for the diagnosis and management of asthma (EPR-3); 2007. Available from: http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines. Accessed 31 Jan 2019.
- 10.Edmonds ML, Millan SJ, Camargo CA Jr, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12.Google Scholar
- 11.Edmonds ML, Millan SJ, Brenner BE, Camargo CA Jr, Rowe BH. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev. 2012;12:CD002316.Google Scholar
- 14.• Kew KM, Quinn M, Quon BS, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2016;6:CD007524. Reviews the data on increasing inhaled corticosteroids during exacerbations.Google Scholar
- 24.• Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting B-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319:1485–96. This paper is a meta-analysis of SMART versus inhaled corticosteroids with and without LABA as controller therapy for persistent asthma.CrossRefGoogle Scholar